Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients
Psychomotor Agitation
About this trial
This is an interventional treatment trial for Psychomotor Agitation
Eligibility Criteria
Inclusion Criteria:
- Trauma/surgical patients admitted to the trauma/surgical ICU
Exclusion Criteria:
- sustained RASS of -4/-5 during the complete ICU admission
- presence of a condition preventing delirium assessment
- anticipated or known ICU length of stay of less than 48 hours
- taking antipsychotics prior to admission
- history of schizophrenia, epilepsy, parkinsonism, or levodopa treatment
- primary neurologic event/injury with GCS ≤ 9 during the first 48 hours of ICU
- current treatment with a continuous infusion neuromuscular blocking agent
- pregnancy
- screened positive for delirium upon admission to the ICU.
Sites / Locations
- University of Tennessee Medical Center
Arms of the Study
Arm 1
Arm 2
No Intervention
Active Comparator
Standard Care
Quetiapine
Standard care for delerium
Quetiapine therapy was initiated at 12.5 mg twice daily a. After thefirst dose of quetiapine 12.5 mg, the regimen could then be adjusted by the rounding surgeon. If the surgeon felt benefit from receiving a higher dose of quetiapine the dose could then be increased. Quetiapine was discontinued if adverse events (torsades de pointes or other ventricular tachycardias) occurred. All patients receiving at least one dose of quetiapine were included in the final intention-to-treat analyses. All prescribing decisions were left to the discretion of the rounding surgeon and were not mandated as part of the study.